JP4643910B2 - 抗癌活性を有する置換インダゾール - Google Patents

抗癌活性を有する置換インダゾール Download PDF

Info

Publication number
JP4643910B2
JP4643910B2 JP2003576408A JP2003576408A JP4643910B2 JP 4643910 B2 JP4643910 B2 JP 4643910B2 JP 2003576408 A JP2003576408 A JP 2003576408A JP 2003576408 A JP2003576408 A JP 2003576408A JP 4643910 B2 JP4643910 B2 JP 4643910B2
Authority
JP
Japan
Prior art keywords
indazol
benzenesulfonamide
phenyl
aryl
methanesulfonylbenzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003576408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533004A (ja
JP2005533004A5 (enExample
Inventor
ドミニク・ダムール
ジャン−クリストフ・カリ
パトリック・ネメセク
コリン・テリエ
フレデリコ・ナルディ
ブリュノ・フィロシュ
マリ−ピエール・シェリエ
ダニエル・ベザール
Original Assignee
アベンティス・ファーマ・ソシエテ・アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベンティス・ファーマ・ソシエテ・アノニム filed Critical アベンティス・ファーマ・ソシエテ・アノニム
Publication of JP2005533004A publication Critical patent/JP2005533004A/ja
Publication of JP2005533004A5 publication Critical patent/JP2005533004A5/ja
Application granted granted Critical
Publication of JP4643910B2 publication Critical patent/JP4643910B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
JP2003576408A 2002-03-11 2003-03-07 抗癌活性を有する置換インダゾール Expired - Fee Related JP4643910B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0202996A FR2836914B1 (fr) 2002-03-11 2002-03-11 Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PCT/FR2003/000751 WO2003078402A1 (fr) 2002-03-11 2003-03-07 Indazoles substitues avec une activite anticancereuse

Publications (3)

Publication Number Publication Date
JP2005533004A JP2005533004A (ja) 2005-11-04
JP2005533004A5 JP2005533004A5 (enExample) 2006-04-20
JP4643910B2 true JP4643910B2 (ja) 2011-03-02

Family

ID=27763684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003576408A Expired - Fee Related JP4643910B2 (ja) 2002-03-11 2003-03-07 抗癌活性を有する置換インダゾール

Country Status (29)

Country Link
US (2) US6858638B2 (enExample)
EP (1) EP1487803A1 (enExample)
JP (1) JP4643910B2 (enExample)
KR (1) KR20040091128A (enExample)
CN (1) CN100369899C (enExample)
AR (1) AR038914A1 (enExample)
AU (1) AU2003242808B2 (enExample)
BR (1) BR0308339A (enExample)
CA (1) CA2478540A1 (enExample)
EC (1) ECSP045286A (enExample)
FR (1) FR2836914B1 (enExample)
GT (1) GT200300031A (enExample)
HN (1) HN2003000094A (enExample)
HR (1) HRP20040825A2 (enExample)
IL (2) IL163805A0 (enExample)
MA (1) MA27176A1 (enExample)
MX (1) MXPA04008446A (enExample)
NO (1) NO20044261L (enExample)
OA (1) OA12784A (enExample)
PA (1) PA8566701A1 (enExample)
PE (1) PE20040071A1 (enExample)
PL (1) PL372389A1 (enExample)
RU (1) RU2004130280A (enExample)
SV (1) SV2003001493A (enExample)
TN (1) TNSN04175A1 (enExample)
TW (1) TW200303863A (enExample)
UY (1) UY27712A1 (enExample)
WO (1) WO2003078402A1 (enExample)
ZA (1) ZA200406730B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005014554A1 (en) * 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
FR2864084B1 (fr) * 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
BRPI0515931A (pt) * 2004-09-29 2008-08-12 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
SE0402762D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
SE0402763D0 (sv) * 2004-11-11 2004-11-11 Astrazeneca Ab Nitro indazole derivatives
CN101243051A (zh) * 2005-08-25 2008-08-13 霍夫曼-拉罗奇有限公司 p38 MAP激酶抑制剂及使用它的方法
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007089646A1 (en) 2006-01-31 2007-08-09 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
JP5364875B2 (ja) * 2007-07-16 2013-12-11 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬としてのインダゾール類、ベンゾイソオキサゾール類およびベンゾイソチアゾール類
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2546294T7 (es) * 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CN102247361B (zh) * 2010-05-20 2015-04-29 中国医学科学院药物研究所 5-硝基-1氢-吲唑-3-腈在制备药物中的应用
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN107108556B (zh) 2014-11-03 2020-09-29 艾欧米制药有限公司 药用化合物
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US11926596B2 (en) 2017-07-21 2024-03-12 Kadmon Corporation, Llc Inhibitors of Rho associated coiled-coil containing protein kinase
WO2019046467A1 (en) 2017-08-29 2019-03-07 Rutgers, The State University Of New Jersey INDAZOLES THERAPEUTIC
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
JP2025504415A (ja) * 2022-01-12 2025-02-12 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物
EP4488275A4 (en) 2022-03-04 2025-07-23 Shanghai Yingli Pharm Co Ltd COMPOUND CONTAINING A FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN114605329B (zh) * 2022-03-28 2024-01-26 河南中医药大学 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途
CN119997982A (zh) 2022-09-09 2025-05-13 迈里克斯制药有限公司 包含nmt抑制剂的抗体药物偶联物及其用途
JP2026502949A (ja) 2022-12-30 2026-01-27 アヴィセンナ バイオサイエンシズ インコーポレイテッド アザインドールｒｏｃｋ阻害剤
WO2024254990A1 (zh) 2023-06-16 2024-12-19 上海璎黎药业有限公司 一种杂芳环结构化合物、其药物组合物及应用
AU2024392169A1 (en) * 2023-11-28 2026-06-11 Quantx Biosciences Us, Inc. Bicyclic heteroaryl compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS514505Y2 (enExample) 1971-02-13 1976-02-07
JPH061350B2 (ja) * 1985-07-26 1994-01-05 コニカ株式会社 ハロゲン化銀写真感光材料
NZ331941A (en) 1996-02-22 2000-04-28 Tularik Inc Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis
DE69724811T2 (de) * 1996-07-19 2004-04-08 Tularik, Inc., South San Francisco Pentafluorobenzensulfonamide und analoge
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
AU1818400A (en) 1998-11-12 2000-05-29 Eli Lilly And Company Aryloxime linkers in the solid-phase synthesis of 3-aminobenzisoxazoles
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002083648A1 (fr) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
JP2004536113A (ja) * 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Also Published As

Publication number Publication date
IL163805A0 (en) 2005-12-18
PE20040071A1 (es) 2004-02-13
AR038914A1 (es) 2005-02-02
US20040106667A1 (en) 2004-06-03
US7473701B2 (en) 2009-01-06
JP2005533004A (ja) 2005-11-04
ECSP045286A (es) 2004-10-26
CA2478540A1 (fr) 2003-09-25
SV2003001493A (es) 2003-07-10
US20050059722A1 (en) 2005-03-17
UY27712A1 (es) 2003-09-30
HN2003000094A (es) 2003-12-15
AU2003242808A1 (en) 2003-09-29
HRP20040825A2 (en) 2005-06-30
BR0308339A (pt) 2005-02-01
MA27176A1 (fr) 2005-01-03
KR20040091128A (ko) 2004-10-27
WO2003078402A1 (fr) 2003-09-25
FR2836914B1 (fr) 2008-03-14
TNSN04175A1 (fr) 2007-03-12
US6858638B2 (en) 2005-02-22
PA8566701A1 (es) 2003-12-10
NO20044261L (no) 2004-11-25
FR2836914A1 (fr) 2003-09-12
ZA200406730B (en) 2005-08-24
CN1642922A (zh) 2005-07-20
GT200300031A (es) 2006-05-26
CN100369899C (zh) 2008-02-20
PL372389A1 (en) 2005-07-25
MXPA04008446A (es) 2004-12-06
EP1487803A1 (fr) 2004-12-22
TW200303863A (en) 2003-09-16
AU2003242808B2 (en) 2008-09-18
IL163805A (en) 2009-08-03
RU2004130280A (ru) 2005-06-27
OA12784A (fr) 2006-07-10

Similar Documents

Publication Publication Date Title
JP2005533004A (ja) 抗癌活性を有する置換インダゾール
EP2039685B1 (en) Heterobicyclic compounds as P38 inhibitors
US7521447B2 (en) P38 inhibitors and methods of use thereof
ES2380054T3 (es) Derivados de aminoindazol activos como inhibidores de quinasas, procedimientos para su preparación, y composiciones farmacéuticas que los contienen
AU5785200A (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
BRPI0720589A2 (pt) Derivados de indazol como inibidores da quinase para tratamento do câncer, derivados de indazol como inibidores da quinase para tratamento do câncer
CN101098868A (zh) 取代吲哚、含有它们的组合物、制备方法及用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101116

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101203

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees